文献速递肿瘤 PET/CT核素与放射性配体治疗

使用64Cu-cyclam-RAFT-c(-RGDfK-)4和64Cu-ATSM两种不同放射性药物实现肿瘤内放射性均匀分布,提高小动物肿瘤模型的治疗效果

Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model.
PubMed 文献 · EJNMMI Res · 2018-06-19

本研究在小动物肿瘤模型中提出靶向放射性核素治疗新概念:联合使用αVβ3整合素显像剂64Cu-RaftRGD与乏氧代谢显像剂64Cu-ATSM以改善肿瘤内放射性分布。结果显示两者肿瘤内分布不一致且近乎互补,联合使用可实现更均匀的放射性分布。联合治疗(各18.5 MBq)较任一单药37 MBq持续抑制肿瘤生长和肿瘤细胞增殖并延长小鼠生存,且未见明显不良反应。

要点

  • 64Cu-RaftRGD与64Cu-ATSM的肿瘤内分布不一致且近乎互补,联合使用可实现更均匀的放射性分布。
  • 单药18.5 MBq对肿瘤生长均无显著影响;联合用药(各18.5 MBq)较任一单药37 MBq持续抑制肿瘤生长与增殖并延长生存。
  • 联合用药的肿瘤摄取高于单用64Cu-RaftRGD但低于单用64Cu-ATSM;所有治疗小鼠未见明显不良反应。

核心结论

  • 联合使用64Cu-RaftRGD与64Cu-ATSM因肿瘤内放射性分布更均匀而获得改善的抗肿瘤效果。
  • 作者认为,联合不同放射性药物以改善肿瘤内分布可能是实现更有效、更安全靶向放射性核素治疗的有前景的概念。

研究设计与样本

  • 研究使用皮下接种αVβ3阳性U87MG胶质母细胞瘤异种移植瘤的小鼠。
  • 通过荧光成像和放射自显影观察注射后3小时共注射的Cy5.5-RaftRGD与64Cu-RaftRGD或64Cu-ATSM的肿瘤内分布。
  • 小鼠接受单次静脉给药:溶媒溶液(对照)、18.5或37 MBq的64Cu-RaftRGD或64Cu-ATSM、或联合用药(各18.5 MBq)。
  • 评估指标包括肿瘤体积、肿瘤细胞增殖、体重、生存以及肿瘤和器官的放射性药物摄取。

主要发现

  • Cy5.5-RaftRGD与64Cu-RaftRGD共定位,可作为放射性药物的替代示踪物。
  • Cy5.5-RaftRGD与64Cu-ATSM的肿瘤内分布不一致且近乎互补。
  • 18.5 MBq的64Cu-RaftRGD或64Cu-ATSM单药对肿瘤生长均无显著影响。
  • 联合用药(各18.5 MBq)较任一单药37 MBq持续抑制肿瘤生长和肿瘤细胞增殖并延长小鼠生存。
  • 联合用药的肿瘤摄取高于单用64Cu-RaftRGD但低于单用64Cu-ATSM;肾脏对64Cu-RaftRGD摄取最高,肝脏对64Cu-ATSM摄取最高;所有治疗小鼠未见明显不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present study proposed a new concept for targeted radionuclide therapy (TRT) to improve the intratumoral distribution of radioactivity using two different radiopharmaceuticals. We examined the efficacy of a combination of a tetrameric cyclic Arg-Gly-Asp (cRGD) peptide-based radiopharmaceutical, 64Cu-cyclam-RAFT-c(-RGDfK-)4 (64Cu-RaftRGD, an αVβ3 integrin [αVβ3] tracer), and 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM, a supposed tracer for hypoxic metabolism) in a small animal tumor model. RESULTS: Mice with subcutaneous αVβ3-positive U87MG glioblastoma xenografts were used. The intratumoral distribution of a near-infrared dye, Cy5.5-labeled RAFT-c(-RGDfK-)4 (Cy5.5-RaftRGD), 64Cu-RaftRGD, and 64Cu-ATSM was visualized by fluorescence imaging and autoradiography of the co-injected Cy5.5-RaftRGD with 64Cu-RaftRGD or 64Cu-ATSM at 3 h postinjection. Mice were treated with a single intravenous dose of the vehicle solution (control), 18.5 or 37 MBq of 64Cu-RaftRGD or 64Cu-ATSM, or a combination (18.5 MBq of each agent). The tumor volume, tumor cell proliferation, body weight, survival, and tumor and organ uptake of radiopharmaceuticals were assessed. It was shown that Cy5.5-RaftRGD colocalized with 64Cu-RaftRGD and could be used as a surrogate for the radioactive agent. The intratumoral distribution of Cy5.5-RaftRGD and 64Cu-ATSM was discordant and nearly complementary, indicating a more uniform distribution of radioactivity achievable with the combined use of 64Cu-RaftRGD and 64Cu-ATSM. Neither 64Cu-RaftRGD nor 64Cu-ATSM showed significant effects on tumor growth at 18.5 MBq. The combination of both (18.5 MBq each) showed sustained inhibitory effects against tumor growth and tumor cell proliferation and prolonged the survival of the mice, compared to that by either single agent at 37 MBq. Interestingly, the uptake of the combination by the tumor was higher than that of 64Cu-RaftRGD alone, but lower than that of 64Cu-ATSM alone. The kidneys showed the highest uptake of 64Cu-RaftRGD, whereas the liver exhibited the highest uptake of 64Cu-ATSM. No obvious adverse effects were observed in all treated mice. CONCLUSIONS: The combination of 64Cu-RaftRGD and 64Cu-ATSM achieved an improved antitumor effect owing to the more uniform intratumoral distribution of radioactivity. Thus, combining different radiopharmaceuticals to improve the intratumoral distribution would be a promising concept for more effective and safer TRT.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Jin ZH, Tsuji AB, Degardin M, et al. Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model. EJNMMI Res. 2018. PMID: 29923139. doi:10.1186/s13550-018-0407-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。